NCT03394885View on ClinicalTrials.gov

Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
Ovarian CancerOvarian Neoplasms
Interventions
DRUG

Atezolizumab

1200mg IV q3weeks

DRUG

Carboplatin

5-6mg/ML IV q3 weeks

DRUG

Paclitaxel

70-80 mg/m2 IV q1 week

DRUG

Bevacizumab

15 mg/kg IV q3 weeks

Trial Locations (3)

21287

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

22908

University of Virginia, Charlottesville

27710

Duke Cancer Institute, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER